NEW YORK, Dec. 10, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) the San Diego-based regenerative medicine company focused on using its breakthrough NovoGen 3D human tissue printing technology to create tissue on demand for medical research and therapeutic applications, today announced that Keith Murphy, CEO, will present at RetailInvestorConferences.com.

Organovo Holdings, Inc.'s presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Organovo Holdings, Inc.:

Organovo (OTCQX: ONVO) designs and creates functional human tissues using a proprietary three-dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications. The Company's NovoGen three-dimensional bioprinting technology employs a specialized automated platform that works across all tissue and cell types. Organovo's bioprinter was named one of the "Best Inventions of 2010" by TIME Magazine and Organovo has been recognized as one of the most innovative companies of 2012 by MIT's Technology Review. Organovo is helping pharmaceutical partners develop never before available human biological disease models in three dimensions that hold the potential to transform the business of therapeutic drug discovery and development. Organovo is also developing direct tissue therapies where precise structure and architecture may deliver the best clinical outcomes. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.